Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines

Biykem Bozkurt, Ildiko Agoston, Anne A Knowlton

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

OBJECTIVES: This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice. BACKGROUND: Spironolactone was reported by one prospective randomized trial to decrease morbidity and mortality in patients with New York Heart Association (NYHA) class III and IV HF. With this report (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread use of spironolactone in patients with HF. Long-term outcome data with respect to safety and utilization of this medication in HF are not available. METHODS: To investigate the use of spironolactone for HF in a clinical setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom we identified as being started on spironolactone for HF after prerelease of the RALES trial. RESULTS: We found broader use, less intensive follow-up, and increased complications with spironolactone treatment compared with the RALES trial. Cardiologists provided more appropriate care than did primary care providers. CONCLUSIONS: These data suggest that spironolactone is being used widely in HF without consideration of the NYHA class and ejection fraction, and without optimization of background treatment with angiotensin-converting enzyme inhibitors and beta-blockers. Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complications. We conclude that long-term studies with further safety and efficacy data are needed.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalJournal of the American College of Cardiology
Volume41
Issue number2
DOIs
StatePublished - Jan 15 2003

Fingerprint

Spironolactone
Heart Failure
Medicine
Guidelines
Safety
Clinical Protocols
Angiotensin-Converting Enzyme Inhibitors
Primary Health Care
Patient Care

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Complications of inappropriate use of spironolactone in heart failure : When an old medicine spirals out of new guidelines. / Bozkurt, Biykem; Agoston, Ildiko; Knowlton, Anne A.

In: Journal of the American College of Cardiology, Vol. 41, No. 2, 15.01.2003, p. 211-214.

Research output: Contribution to journalArticle

@article{8f8a03b5bdda43b4bf1abcaa82bb28e0,
title = "Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines",
abstract = "OBJECTIVES: This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice. BACKGROUND: Spironolactone was reported by one prospective randomized trial to decrease morbidity and mortality in patients with New York Heart Association (NYHA) class III and IV HF. With this report (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread use of spironolactone in patients with HF. Long-term outcome data with respect to safety and utilization of this medication in HF are not available. METHODS: To investigate the use of spironolactone for HF in a clinical setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom we identified as being started on spironolactone for HF after prerelease of the RALES trial. RESULTS: We found broader use, less intensive follow-up, and increased complications with spironolactone treatment compared with the RALES trial. Cardiologists provided more appropriate care than did primary care providers. CONCLUSIONS: These data suggest that spironolactone is being used widely in HF without consideration of the NYHA class and ejection fraction, and without optimization of background treatment with angiotensin-converting enzyme inhibitors and beta-blockers. Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complications. We conclude that long-term studies with further safety and efficacy data are needed.",
author = "Biykem Bozkurt and Ildiko Agoston and Knowlton, {Anne A}",
year = "2003",
month = "1",
day = "15",
doi = "10.1016/S0735-1097(02)02694-3",
language = "English (US)",
volume = "41",
pages = "211--214",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Complications of inappropriate use of spironolactone in heart failure

T2 - When an old medicine spirals out of new guidelines

AU - Bozkurt, Biykem

AU - Agoston, Ildiko

AU - Knowlton, Anne A

PY - 2003/1/15

Y1 - 2003/1/15

N2 - OBJECTIVES: This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice. BACKGROUND: Spironolactone was reported by one prospective randomized trial to decrease morbidity and mortality in patients with New York Heart Association (NYHA) class III and IV HF. With this report (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread use of spironolactone in patients with HF. Long-term outcome data with respect to safety and utilization of this medication in HF are not available. METHODS: To investigate the use of spironolactone for HF in a clinical setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom we identified as being started on spironolactone for HF after prerelease of the RALES trial. RESULTS: We found broader use, less intensive follow-up, and increased complications with spironolactone treatment compared with the RALES trial. Cardiologists provided more appropriate care than did primary care providers. CONCLUSIONS: These data suggest that spironolactone is being used widely in HF without consideration of the NYHA class and ejection fraction, and without optimization of background treatment with angiotensin-converting enzyme inhibitors and beta-blockers. Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complications. We conclude that long-term studies with further safety and efficacy data are needed.

AB - OBJECTIVES: This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice. BACKGROUND: Spironolactone was reported by one prospective randomized trial to decrease morbidity and mortality in patients with New York Heart Association (NYHA) class III and IV HF. With this report (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread use of spironolactone in patients with HF. Long-term outcome data with respect to safety and utilization of this medication in HF are not available. METHODS: To investigate the use of spironolactone for HF in a clinical setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom we identified as being started on spironolactone for HF after prerelease of the RALES trial. RESULTS: We found broader use, less intensive follow-up, and increased complications with spironolactone treatment compared with the RALES trial. Cardiologists provided more appropriate care than did primary care providers. CONCLUSIONS: These data suggest that spironolactone is being used widely in HF without consideration of the NYHA class and ejection fraction, and without optimization of background treatment with angiotensin-converting enzyme inhibitors and beta-blockers. Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complications. We conclude that long-term studies with further safety and efficacy data are needed.

UR - http://www.scopus.com/inward/record.url?scp=0037438820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037438820&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(02)02694-3

DO - 10.1016/S0735-1097(02)02694-3

M3 - Article

C2 - 12535810

AN - SCOPUS:0037438820

VL - 41

SP - 211

EP - 214

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -